2,130 Shares in Moderna, Inc. $MRNA Purchased by Philadelphia Trust Co.

Philadelphia Trust Co. bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,130 shares of the company’s stock, valued at approximately $410,000.

Other hedge funds have also made changes to their positions in the company. Mesirow Financial Investment Management Inc. bought a new stake in shares of Moderna in the third quarter worth $383,000. Lido Advisors LLC raised its holdings in Moderna by 0.5% in the third quarter. Lido Advisors LLC now owns 16,605 shares of the company’s stock valued at $3,198,000 after acquiring an additional 83 shares in the last quarter. Keybank National Association OH boosted its stake in Moderna by 5.6% during the 3rd quarter. Keybank National Association OH now owns 9,581 shares of the company’s stock valued at $1,845,000 after acquiring an additional 512 shares during the last quarter. 71 West Capital Partners bought a new position in Moderna during the 3rd quarter valued at $494,000. Finally, Gryphon Financial Partners LLC bought a new position in Moderna during the 3rd quarter valued at $470,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on MRNA. Jefferies Financial Group reissued a “hold” rating and issued a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Morgan Stanley upped their target price on shares of Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a research report on Wednesday, October 21st. Rothschild & Co Redburn downgraded Moderna from a “neutral” rating to a “sell” rating and lifted their price target for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft began coverage on Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 price target for the company. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $113.75.

Insider Transactions at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock valued at $33,875,904 in the last quarter. Insiders own 10.80% of the company’s stock.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Moderna Price Performance

NASDAQ:MRNA opened at $250.83 on Wednesday. The business’s 50-day moving average price is $196.68 and its 200 day moving average price is $93.60. The firm has a market cap of $101.49 billion, a P/E ratio of -35.33 and a beta of 1.16. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same period in the previous year, the business earned ($0.51) earnings per share. Moderna’s revenue for the quarter was up 29.2% compared to the same quarter last year. As a group, sell-side analysts predict that Moderna, Inc. will post -5.69 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.